Clinical Pharmacology Profile of Boceprevir, a Hepatitis C Virus NS3 Protease Inhibitor: Focus on Drug–Drug Interactions

Clinical Pharmacokinetics

Volumn 54, Issue 6, 2015, Pages 599-614

  Khalilieh, Sauzanne ^a   Feng, Hwa Ping ^a   Hulskotte, Ellen G J ^b,c   Wenning, Larissa A ^a   Butterton, Joan R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NV ORGANON   (Netherlands)

^c Treeway   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BOCEPREVIR; CYCLOSPORIN A; DOLUTEGRAVIR; EFAVIRENZ; ETRAVIRINE; MARAVIROC; PREDNISONE; PROTEINASE INHIBITOR; RALTEGRAVIR; RAPAMYCIN; RILPIVIRINE; RITONAVIR; TACROLIMUS; TENOFOVIR; ANTIVIRUS AGENT; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; NS3 PROTEIN, HEPATITIS C VIRUS; PROLINE; RIBAVIRIN; VIRUS PROTEIN;

BLOOD LEVEL; CLINICAL PHARMACOLOGY; COMORBIDITY; DRUG INTERACTION; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IN VITRO STUDY; KIDNEY FAILURE; METABOLISM; PRIORITY JOURNAL; REVIEW; TISSUE DISTRIBUTION; WHOLE BODY IMAGING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG COMBINATION; DRUG EFFECTS; HEPATITIS C, CHRONIC; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; PROLINE; PROTEASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBAVIRIN; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84930085341     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-015-0260-8     Document Type: Review

References (59)

1. Venkatraman S, Bogen SL, Arasappan A, et al. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. J Med Chem. 2006;49:6074–86.
2. Malcolm BA, Liu R, Lahser F, et al. SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother. 2006;50:1013–20.
3. Poordad F, McCone J, Bacon BR, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.
4. Bacon B, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.
5. ® (boceprevir) capsules [prescribing information]. Whitehouse Station: Merck & Co., Inc; 2011.
6. Chu X, Cai X, Cui D, et al. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters. Drug Metab Dispos. 2013;41:668–81.
7. Ghosal A, Yuan Y, Tong W, et al. Characterization of human liver enzymes involved in the biotransformation of boceprevir, a HCV protease inhibitor. Drug Metab Dispos. 2011;39:510–21.
8. Gordon SC, Yoshida EM, Lawitz EJ, et al. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther. 2013;38:16–27.
9. Poordad FF, Lawitz E, Gordon SC, et al. Concomitant medication use in patients with hepatitis C genotype 1 treated with boceprevir (BOC) combination therapy. Hepatology. 2011;54:739A.
10. Kasserra C, Treitel M, Hughes E, et al. Effect of food on the pharmacokinetics of boceprevir in Japanese and Caucasian healthy subjects. Hepatol Int. 2015;5:258–9.
11. Treitel M, Marbury T, Preston RA, et al. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function. Clin Pharmacokinet. 2012;51:619–28.
12. Monga HK, Rodriguez-Barradas MC, Breaux K, et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;33:240–7.
13. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001;33:562–9.
14. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004;292:2839–48.
15. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351:451–9.
16. Sulkowski MS. Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis. 2013;207(Suppl 1):S26–32.
17. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clin Infect Dis. 2013;56:718–26.
18. Vourvahis M, Plotka A, Kantaridis C, et al. The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers. J Acquir Immune Defic Syndr. 2014;65:564–70.
19. de Kanter CT, Blonk MI, Colbers AP, et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the hepatitis C virus protease inhibitor boceprevir and the HIV integrase inhibitor raltegravir. Clin Infect Dis. 2012;56:300–6.
20. Johnson M, Borland J, Chen S, et al. Effects of boceprevir and telaprevir on the pharmacokinetics of dolutegravir. Br J Clin Pharmacol. 2014;78:1043–9.
21. Hammond KP, Wolfe P, Burton JR Jr, et al. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers. J Acquir Immune Defic Syndr. 2013;62:67–73.
22. Kiser JJ, Lu D, Rosenkranz SL, et al. Boceprevir and antiretroviral pharmacokinetic interactions in HIV/HCV co-infected persons. AIDS Clinical Trials Group Study A5309s. Presented at the 15th International Workshop of Clinical Pharmacology of HIV and Hepatitis Therapy; Washington, DC, 19–21 May 2014.
23. Dolton MJ, Ray JE, McLachlan AJ. Telaprevir and boceprevir: a potential role for therapeutic drug monitoring. Ther Drug Monit. 2013;35:414–5.
24. Hulskotte E, Gupta S, Xuan F, et al. Pharmacokinetic interaction between the HVC protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology. 2012;56:1622–30.
25. Sam T, Tichy E, Emre S, et al. Pharmacokinetic effects of boceprevir co-administration on cyclosporine exposure in liver transplant recipients. Am J Transplant. 2012;12:430–1.
26. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29:404–30.
27. Sanabria JA, Sanchez MB, Fabrega E, et al. Management of boceprevir and tacrolimus in a patient with liver transplant and hepatitis c virus recurrence. Basic Clin Pharmacol Toxicol. 2013;113:2.
28. Sattler M, Guengerich FP, Yun CH, et al. Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos. 1992;20:753–61.
29. Gallant-Haidner HL, Trepanier DJ, Freitag DG, et al. Pharmacokinetics and metabolism of sirolimus. Ther Drug Monit. 2000;22:31–5.
30. Rapamune (sirolimus) oral solution and tablets [prescribing information]. Philadelphia: Wyeth Pharmaceuticals Inc.; 2010.
31. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic interactions between the HCV protease inhibitor boceprevir and sirolimus in healthy subjects. J Hepatol. 2013;58:S190.
32. Frey BM, Frey FJ. Clinical pharmacokinetics of prednisone and prednisolone. Clin Pharmacokinet. 1990;19:126–46.
33. Jumes P, Feng HP, Chatterjee M, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and prednisone in healthy volunteers. Hepatology. 2014;56:1076A.
34. Bruce RD, Moody DE, Altice FL, et al. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013;6:249–69.
35. Hulskotte EGJ, Bruce RD, Feng HP, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. Eur J Clin Pharmacol. 2015;71:303–11.
36. Hulskotte E, Feng HP, Bruce RD, et al. Pharmacokinetic interaction between HCV protease inhibitor boceprevir and methadone or buprenorphine in subjects on stable maintenance therapy. Rev Antiviral Ther Infect Dis. 2012;6:12.
37. Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet. 2005;44:661–80.
38. Fang WB, Chang Y, Cance-Katz EF, et al. Determination of naloxone and nornaloxone (noroxymorphone) by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry. J Anal Toxicol. 2009;33:409–17.
39. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003;70:S39–47.
40. Yaz (drospirenone and ethinyl estradiol) tablets [prescribing information]. Wayne: Bayer Healthcare Pharmaceuticals Inc; 2010.
41. Korhonen T, Turpeinen M, Tolonen A, et al. Identification of the human cytochrome P450 enzymes involved in the in vitro biotransformation of lynestrenol and norethindrone. J Steroid Biochem Mol Biol. 2008;110:56–66.
42. Lin WH, Feng HP, Chatterjee M, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and ethinyl estradiol/norethindrone. Hepatology. 2012;56:1078A–9A.
43. Lin WH, Feng HP, Shadle CR, et al. Pharmacokinetic and pharmacodynamic interactions between the hepatitis C virus protease inhibitor, boceprevir, and the oral contraceptive ethinyl estradiol/norethindrone. Eur J Clin Pharmacol. 2014;70:1107–13.
44. Lennernas H. Clinical pharmacokinetics of atorvastatin. Clin Pharmacokinet. 2003;42:1141–60.
45. Hulskotte EG, Feng HP, Xuan F, et al. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin. Antimicrob Agents Chemother. 2013;57:2582–8.
46. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343–70.
47. Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin, and pravastatin. Clin Pharmacokinet. 2008;47:463–74.
48. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther. 2006;112:71–105.
49. Mayer U, Wagenaar E, Beijnen JH, et al. Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein. Br J Pharmacol. 1996;119:1038–44.
50. Jumes P, Feng HP, Xuan F, et al. Pharmacokinetic interaction between the HCV protease inhibitor boceprevir and digoxin in healthy adult volunteers. Rev Antiviral Ther Infect Dis. 2012;6:8.
51. LEXAPRO (escitalopram oxalate) tablets and oral solution [prescribing information]. St Louis: Forest Pharmaceuticals, Inc.; 2011 May.
52. Hulskotte EGJ, Gupta S, Xuan F, et al. Coadministration of the HCV protease inhibitor boceprevir has no clinically meaningful effect on the pharmacokinetics of the selective serotonin reuptake inhibitor escitalopram in healthy volunteers. Presented at the 16th Annual Meeting of HEP DART; Koloa (HI), 4–8 Dec 2011.
53. de Kanter CT, Colbers AP, Blonk MI, et al. Lack of a clinically significant drug-drug interaction in healthy volunteers between the HCV protease inhibitor boceprevir and the proton pump inhibitor omeprazole. J Antimicrob Agents Chemother. 2013;68:1415–22.
54. Jackson A, D’Avolio A, Moyle G, et al. Pharmacokinetics of the co-administration of boceprevir and St John’s wort to male and female healthy volunteers. J Antimicrob Chemother. 2014;69:1911–5.
55. Wire MB, Fang L, Hussaini A, et al. Lack of clinically significant pharmacokinetic interaction between the thrombopoietin receptor agonist eltrombopag and hepatitis C virus protease inhibitors boceprevir and telaprevir. Antimicrob Agents Chemother. 2014;58:6704–9.
56. Kasserra C, Treitel M, Hughes EA, et al. Effect of boceprevir on red blood cells and markers of anemia in healthy volunteers. Gastroenterology. 2015;140:s945.
57. Wenning LA, Flexner C, Liu R, et al. Assessment of boceprevir (VICTRELIS™) pharmacokinetic/pharmacodynamic relationships for sustained viral response (SVR) and occurrence of anemia results in HCV/HIV co-infected patients and in combined mono-and co-infected patients. Hepatology. 2015;56:564A.
58. American Association for the Study of Liver Diseases, Infectious Diseases Society of North America. Recommendations for testing, managing, and treating hepatitis C. Available at: http://www.hcvguidelines.org. Accessed 26 May 2014.
59. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatitis C virus infection. J Hepatol. 2014;60:392–420.